In vitro activity of bedaquiline against Mycobacterium fortuitum complex
https://doi.org/10.54921/2413-0346-2024-12-1-30-35
Abstract
The activity of bedaquiline (Bdq), a drug that is effectively used for the treatment of tuberculosis, including those with multiple (MDR) and extensively drug resistant (XDR) pathogen, was studied against rapidly growing non-tuberculous mycobacteria (NTM) belonging to Mycobacterium fortuitum complex (MFC).
Methods. А total 154 strains of MFC (78 of M. fortuitum and 76 of M. peregrinum) were examined. In addition, the drug susceptibility (DS) of these strains to 15 antibacterial drugs (ABD) was studied using the Sensitititre RapMyco test system.
Results. Тhe Bdq MIC range for M. fortuitum was found to be 0.0015–1.0 μg/mL, M. peregrinum – 0.0015–2.0 μg/mL. The MIC50 for M. fortuitum was 0.015 µg/mL, MIC90 was 0.25 µg/mL, and ECOFF was 0.5 µg/mL. For M. peregrinum, the corresponding values were 0.007, 0.06 and 2.0 µg/mL. As a result, only 1 (1.3%) resistant strain of M. fortuitum was detected, no resistant strains of M. peregrinum were found. When the DS of these NTM species to other ABDs were studied, it was found that M. fortuitum and M. peregrinum were highly resistant to most of them.
Conclusion. Bdq was found to be active against MFC in vitro and is likely to be effective in the chemotherapy of mycobacteriosis caused by these NTM species.
About the Authors
M. V. Makarova
Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Health Department (MRCCTC)
Russian Federation
Russian Federation
Y. D. Mikhailova
Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Health Department (MRCCTC)
Russian Federation
Russian Federation
M. A. Sviridenko
Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Health Department (MRCCTC)
Russian Federation
Russian Federation
E. N. Khachaturyants
Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Health Department (MRCCTC)
Russian Federation
Russian Federation
V. I. Litvinov
Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Health Department (MRCCTC)
Russian Federation
Russian Federation
References
1. Богородская Е.М., Кудлай Д.А., Литвинов В.И. Проблемы лекарственной устойчивости микобактерий / Под ред. Е.М. Богородской, Д.А. Кудлая, В.И. Литвинова. – М.: МНПЦБТ, 2021. – 504 с.
2. Борисов С.Е., Иванушкина Т.Н., Иванова Д.А., Филиппов А.В., Литвинова Н.В., Родина О.В., Гармаш Ю.Ю., Сафонова С.Г., Богородская Е.М. Эффективность и безопасность включающих бедаквилин шестимесячных режимов химиотерапии у больных туберкулезом органов дыхания // Туберкулез и социально значимые заболевания. – 2015. – №3. – C. 30-49.
3. Литвинов В.И., Богородская Е.М., Борисов С.Е. Нетуберкулезные микобактерии, микобактериозы / Под ред. В.И. Литвинова, Е.М. Богородской, С.Е. Борисова. – М.: МНПЦБТ, 2014. – 256 с.
4. Aguilar-Ayala D.A., Cnockaert M., André E., Andries K., Gonzalez-Y-Merchand J.A., Vandamme P., Palomino J.C., Martin A. In vitro activity of bedaquiline against rapidly growing nontuberculous mycobacteria // J. Med. Microbiol. – 2017. – Vol. 66, № 8. – P. 1140-1143. doi: 10.1099/jmm.0.000537.
5. Alffenaar J.W., Märtson A.G., Heysell S.K., Cho J.G., Patanwala A., Burch G., Kim H.Y., Sturkenboom M.G.G., Byrne A., Marriott D, Sandaradura I, Tiberi S, Sintchencko V, Srivastava S, Peloquin CA. Therapeutic drug monitoring in non-tuberculosis mycobacteria infections // Clin. Pharmacokinet. – 2021. – Vol. 60, № 6. – P. 711-725. doi: 10.1007/s40262-021-01000-6.
6. Andries K., Villellas C., Coeck N., Thys K., Gevers T., Vranckx L., Lounis N., de Jong B.C., Koul A. Acquired resistance of Mycobacterium tuberculosis to bedaquiline // PLoS One. – 2014. - Vol. 10, № 9(7). – P. e102135. doi: 10.1371/journal.pone.0102135.
7. Brown-Elliott B.A., Nash K.A., Wallace R.J. Jr. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria // Clin. Microbiol. Rev. – 2012. – Vol. 25, № 3. – P. 545-582. doi: 10.1128/CMR.05030-11.
8. Brown-Elliott B.A., Philley J.V., Griffith D.E., Thakkar F., Wallace R.J. Jr. In vitro susceptibility testing of bedaquiline against Mycobacterium avium complex // Antimicrob. Agents Chemother. - 2017. – Vol. 24, № 61(2). – P. e01798-16. doi: 10.1128/AAC.01798-16.
9. Brown-Elliott B.A., Wallace R.J. Jr. In vitro susceptibility testing of bedaquiline against Mycobacterium abscessus complex // Antimicrob. Agents Chemother. – 2019. – Vol. 29, № 63(2). – P. e01919-18. doi: 10.1128/AAC.01919-18.
10. Clinical and Laboratory Standards Institute (CLSI). Susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes. – 3rd ed. – Wayne, PA, USA, 2018.
11. Erber J., Weidlich S., Tschaikowsky T., Rothe K., Schmid R.M., Schneider J., Spinner C.D. Successful bedaquiline-containing antimycobacterial treatment in post-traumatic skin and soft-tissue infection by Mycobacterium fortuitum complex: a case report // BMC Infect. Dis. – 2020. – Vol. 24, № 20(1). – P. 365. doi: 10.1186/s12879-020-05075-7.
12. European Committee on Antimicrobial Susceptibility Testing. EUCAST subcommittee on MIC distributions and epidemiological cut-off values (ECOFFs). 2014. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Consul-tation/2017/MIC_and_ECOFF/EUCAST_MIC_and_ECOFF_discussion_document_version_3_20170309.pdf.
13. Falkinham J.O. 3rd Ecology of nontuberculous mycobacteria // Microorganisms. – 2021. – Vol. 30, № 9(11). – P. 2262. doi: 10.3390/microorganisms9112262.
14. Griffith D.E., Aksamit T., Brown-Elliott B.A., Catanzaro A., Daley C., Gordin F., Holland S.M., Horsburgh R., Huitt G., Iademarco M.F., Iseman M., Olivier K., Ruoss S., von Reyn C.F., Wallace R.J. Jr, Winthrop K. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases / ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America // Am. J. Respir. Crit. Care Med. – 2007. – Vol. 15, № 175(4). – P. 367-416. doi: 10.1164/rccm.200604-571ST.
15. Hagiwara E., Sekine A., Sato T., Baba T., Shinohara T., Endo T., Sogo Y., Nishihira R., Komatsu S., Matsumoto Y., Ogura T., Takahashi H. Clinical features of pulmonary disease caused by Mycobacterium fortuitum // Nihon Kokyuki Gakkai Zasshi [Japanese]. – 2008. – Vol. 46, № 10. – P. 788-792.
16. Huitric E., Verhasselt P., Andries K., Hoffner S.E. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor // Antimicrob. Agents Chemother. – 2007. – Vol. 51, № 11. – P. 4202-4204. doi: 10.1128/AAC.00181-07.
17. Hypolite T., Grant-Kels J.M., Chirch L.M. Nontuberculous mycobacterial infections: a potential complication of cosmetic procedures // Int. J. Womens Dermatol. – 2015. – Vol. 24, , № 1(1). – P. 51-54. doi: 10.1016/j.ijwd.2014.12.007.
18. Ismail N., Rivière E., Limberis J., Huo S., Metcalfe J.Z., Warren R.M., Van Rie A. Genetic variants and their association with phenotypic resistance to bedaquiline in Mycobacterium tuberculosis: a systematic review and individual isolate data analysis // Lancet Microbe. – 2021. – Vol. 2, № 11. – P. e604-e616. doi: 10.1016/s2666-5247(21)00175-0.
19. Johnson T.M., Byrd T.F., Drummond W.K., Childs-Kean L.M., Mahoney M.V., Pearson J.C., Rivera C.G. Contemporary pharmacotherapies for nontuberculosis mycobacterial infections: a narrative review // Infect. Dis. Ther. – 2023. – Vol. 12, № 2. – P. 343-365. doi: 10.1007/s40121-022-00750-5.
20. Kim D.H., Jhun B.W., Moon S.M., Kim S.Y., Jeon K., Kwon O.J., Huh H.J., Lee N.Y., Shin S.J., Daley C.L., Koh W.J. In vitro activity of bedaquiline and delamanid against nontuberculous mycobacteria, including macrolide-resistant clinical isolates // Antimicrob. Agents Chemother. – 2019. –Vol. 63, № 8. – P. e00665-19. doi: 10.1128/AAC.00665-19.
21. Kim S.R., Yu J.Y., Kim S.Y., Kim D.H., Jhun B.W. Clinical characteristics and treatment outcomes of Mycobacterium fortuitum pulmonary disease // Microbiol. Spectr. – 2023. – Vol. 11, № 4. - P. e0205123. doi: 10.1128/spectrum.02051-23
22. Kumar C., Shrivastava K., Singh A., Chauhan V., Varma-Basil M. Skin and soft-tissue infections due to rapidly growing mycobacteria: An overview // Int. J. Mycobacteriol. – 2021. – Vol. 10, № 3. – P. 293-300. doi: 10.4103/ijmy.ijmy_110_21.
23. Lao C.K., Wu T.S., Lin K.Y., Lee M.H. Disseminated Mycobacterium peregrinum and Mycobacterium avium infection in a patient with AIDS: A case report and review of literature // J. Clin. Tuberc. Other Mycobact. Dis. – 2022. – Vol. 12, № 27. – P. 100314. doi: 10.1016/j.jctube.2022.100314.
24. Meldrum O.W., Belchamber K.B.R., Chichirelo-Konstantynovych K.D., Horton K.L., Konstantynovych T.V., Long M.B., McDonnell M.J., Perea L., Garcia-Basteiro A.L., Loebinger M.R., Duarte R., Keir H.R. ERS International Congress 2021: highlights from the Respiratory Infections Assembly // ERJ Open Res. – 2022. – Vol. 23, № 8(2). – P. 00642-2021. doi: 10.1183/23120541.00642-2021.
25. Mhaske A.N., Mhaske S., Harke S., Jain A., Patel J., Mhaske S. Postsurgical non-tuberculous mycobacterium: a case series // Cureus. – 2022. – Vol. 3, № 14(5). – P. e24701. doi: 10.7759/cureus.24701.
26. Pang H., Li G., Zhao X., Liu H., Wan K., Yu P. Drug susceptibility testing of 31 antimicrobial agents on rapidly growing mycobacteria isolates from China // Biomed. Res. Int. – 2015. – Vol. 2015. – P. 419392. doi: 10.1155/2015/419392.
27. Pavlik I., Ulmann V., Falkinham J.O. 3rd Nontuberculous mycobacteria: ecology and impact on animal and human health // Microorganisms. – 2022. – Vol. 27, № 10(8). – P. 1516. doi: 10.3390/microorganisms10081516.
28. Philley J.V., Wallace R.J. Jr, Benwill J.L., Taskar V., Brown-Elliott B.A, Thakkar F., Aksamit T.R., Griffith D.E. Preliminary results of bedaquiline as salvage therapy for patients with nontuberculous mycobacterial lung disease // Chest. – 2015. – Vol. 148, № 2. – P. 499-506. doi: 10.1378/chest.14-2764.
29. Ratnatunga C.N., Lutzky V.P., Kupz A., Doolan D.L., Reid D.W., Field M., Bell S.C., Thomson R.M., Miles J.J. The rise of non-tuberculosis mycobacterial lung disease // Front Immunol. – 2020. – Vol. 11. – P. 303. doi: 10.3389/fimmu.2020.00303.
30. Van Ingen J., Blaak H., de Beer J., de Roda Husman A.M., van Soolingen D. Rapidly growing nontuberculous mycobacteria cultured from home tap and shower water // Appl. Environ. Microbiol. – 2010. – Vol. 76, № 17. – P. 6017-6019. doi: 10.1128/AEM.00843-10.
31. Van Ingen J., Boeree M.J., van Soolingen D., Mouton J.W. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria // Drug Resist. Updat. – 2012. – Vol. 15, № 3. – P. 149-161. doi: 10.1016/j.drup.2012.04.001.
32. Vesenbeckh S., Schönfeld N., Krieger D., Bettermann G., Bauer T.T., Rüssmann H., Mauch H. Bedaquiline as a potential agent in the treatment of M. intracellulare and M. avium infections // Eur. Respir. J. – 2017. – Vol. 22, № 49(3). – P. 1601969. doi: 10.1183/13993003. 01969-2016.
33. Vesenbeckh S., Schönfeld N., Roth A., Bettermann G., Krieger D., Bauer T.T., Rüssmann H., Mauch H. Bedaquiline as a potential agent in the treatment of Mycobacterium abscessus infections // Eur. Respir. J. – 2017. – Vol. 49, № 5. – P. 1700083. doi: 10.1183/13993003. 00083-2017.
34. Wang M.G., Wu S.Q., He J.Q. Efficacy of bedaquiline in the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis // BMC Infect. Dis. – 2021. – Vol. 21, № 1. – P. 970. doi: 10.1186/s12879-021-06666-8.
35. WHO consolidated guidelines on tuberculosis: Module 4: treatment – drug-resistant tuberculosis treatment, 2022 update [Internet]. – Geneva: World Health Organization, 2022.
36. Yu X., Gao X., Li C., Luo J., Wen S., Zhang T., Ma Y., Dong L., Wang F., Huang H. In vitro activities of bedaquiline and delamanid against nontuberculous mycobacteria isolated in Beijing, China // Antimicrob. Agents Chemother. – 2019. – Vol. 63, № 8. – P. e00031-19. doi: 10.1128/AAC.00031-19.
37. Zheng H.W., Pang Y., He G.X., Song Y.Y., Zhao Y.L. Antimicrobial susceptibility testing and molecular characterization of Mycobacterium fortuitum isolates in China // Biomed. Environ. Sci. – 2017. – Vol. 30, № 5. – P. 376-379. doi: 10.3967/bes2017.049
Review
For citations:
Makarova M.V., Mikhailova Y.D., Sviridenko M.A., Khachaturyants E.N., Litvinov V.I. In vitro activity of bedaquiline against Mycobacterium fortuitum complex. Tuberculosis and socially significant diseases. 2024;12(1):30-35. (In Russ.) https://doi.org/10.54921/2413-0346-2024-12-1-30-35
Views:
104
Email this article 